|
|
||||||||
1Division of Nephrology, Departments of Internal Medicine and Pathology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, Arkansas; and 2Division of Nephrology Department of Medicine University of Virginia, Charlottesville Virginia
Submitted 28 January 2005 ; accepted in final form 29 March 2005
Recently, we demonstrated that peroxisome proliferator-activated receptor-
(PPAR
) ligand ameliorates cisplatin-induced acute renal failure (ARF) by preventing inhibition of substrate oxidation, and also by preventing apoptosis and necrosis of the proximal tubule (Li S, Bhatt R, Megyesi J, Gokden N, Shah SV, and Portilla D. Am J Physiol Renal Physiol 287: F990F998, 2004). In the following studies, we examined the protective effect of PPAR
ligand on cisplatin-induced inflammatory responses during ARF. Mice subjected to a single intraperitoneal injection of cisplatin developed ARF at day 3. Cisplatin increased mRNA and protein expression of TNF-
, RANTES, and also upregulated endothelial adhesion molecules ICAM-1/VCAM-1 and chemokine receptors CCR1/CCR5. Cisplatin also led to neutrophil infiltration in the corticomedullary region. Pretreatment of wild-type mice with WY-14,643, a fibrate class of PPAR
ligands, before cisplatin significantly suppressed cisplatin-induced upregulation of cytokine/chemokine expression, prevented neutrophil accumulation, and ameliorated renal dysfunction. In contrast, treatment with PPAR
ligand before cisplatin did not prevent cytokine/chemokine production, neutrophil accumulation, and did not protect kidney function in PPAR
null mice. In addition, we observed that cisplatin-induced NF-
B binding activity in nuclear extracts from wild-type mice was markedly reduced by treatment with PPAR
ligand. These results demonstrate that PPAR
exerts an anti-inflammatory effect in kidney tissue by a mechanism that includes inhibition of NF-
B DNA binding activity, and this effect results in inhibition of neutrophil infiltration, cytokine/chemokine release, and amelioration of cisplatin-induced ARF.
peroxisome proliferator-activated receptor-
; inflammation; cisplatin; acute renal failure
This article has been cited by other articles:
![]() |
M. Jiang and Z. Dong Regulation and Pathological Role of p53 in Cisplatin Nephrotoxicity J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 300 - 307. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Liu, Z. Jia, S. Soodvilai, G. Guan, M.-H. Wang, Z. Dong, J. D. Symons, and T. Yang Nitro-oleic acid protects the mouse kidney from ischemia and reperfusion injury Am J Physiol Renal Physiol, October 1, 2008; 295(4): F942 - F949. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Luo, T. Tsuji, H. Yasuda, Y. Sun, Y. Fujigaki, and A. Hishida The molecular mechanisms of the attenuation of cisplatin-induced acute renal failure by N-acetylcysteine in rats Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2198 - 2205. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kindt, A. Menzebach, M. Van de Wouwer, I. Betz, A. De Vriese, and E. M. Conway Protective role of the inhibitor of apoptosis protein, survivin, in toxin-induced acute renal failure FASEB J, February 1, 2008; 22(2): 510 - 521. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H. Lu, D.-J. Oh, B. Dursun, Z. He, T. S. Hoke, S. Faubel, and C. L. Edelstein Increased Macrophage Infiltration and Fractalkine Expression in Cisplatin-Induced Acute Renal Failure in Mice J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 111 - 117. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kamijo, K. Hora, K. Kono, K. Takahashi, M. Higuchi, T. Ehara, K. Kiyosawa, H. Shigematsu, F. J. Gonzalez, and T. Aoyama PPAR{alpha} Protects Proximal Tubular Cells from Acute Fatty Acid Toxicity J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3089 - 3100. [Full Text] [PDF] |
||||
![]() |
L. Baud and E. Letavernier PPAR{alpha} Contributes to Tubular Protection J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3017 - 3018. [Full Text] [PDF] |
||||
![]() |
S. K. Jo, M. H. Rosner, and M. D. Okusa Pharmacologic Treatment of Acute Kidney Injury: Why Drugs Haven't Worked and What Is on the Horizon Clin. J. Am. Soc. Nephrol., March 1, 2007; 2(2): 356 - 365. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Zager, A. C. M. Johnson, S. Lund, and J. Randolph-Habecker Toll-like receptor (TLR4) shedding and depletion: acute proximal tubular cell responses to hypoxic and toxic injury Am J Physiol Renal Physiol, January 1, 2007; 292(1): F304 - F312. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Boulanger, R. Mansouri, J. F. Gautier, and D. Glotz Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies? Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2696 - 2702. [Full Text] [PDF] |
||||
![]() |
M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR) Toxicol. Sci., April 1, 2006; 90(2): 269 - 295. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |